Research lines

• Therapeutic aspects

  The following lines are mainly focussed on clinical and diagnostic features of HIV & co-infection:

  • HCV and HBV coinfection. Efficacy and safety of new direct-antiviral drugs (DAA) against HCV. Long- term follow up of patients treated with DAA. Strategies toward HCV eradication
  • Antiretroviral treatment: efficacy and safety of new antiretroviral drugs
  • Studies of resistance
  • New antiretroviral strategies
  • Primary HIV infection: eradication and functional cure strategies
  • Use of Tirosine Knase inhibitors as a new strategy for HIV cure

• Clinical and diagnostic aspects

  • Pharmacogenomics and pharmacokinetics
  • Opportunistic diseases associated to HIV infection: tuberculosis, human papillomavirus, anal cancer
  • Solid organ transplantation in HIV-infected patients
  • Incidence and management of non-AIDS defining events including infections, cardiovascular diseases, frailty, cancer and accelerated aging.
  • Early diagnosis and treatment of HCV reinfection
  • Pregnancy and HIV
  • Impact evolution and prognostic factor of COVID-19 in HIV patients
  • Immunological response of HIV patients to SARS-CoV-2 vaccines

• Basic and translational research

  • Immuno-pathogenesis of HIV infection and mechanisms of HIV control
  • Generation of new immunogens based on defective HIV-based vectors 
  • Development of new therapeutic vaccines platforms: dendritic cells and RNA-based vaccines
  • Preventive vaccines based on the envelope of Transmitted-Founder Viruses
  • Studies on the HIV reservoirs in different clinical situations. Impact of tumour events in the maintenance of viral reservoirs.
  • Impact of tumour events in the maintenance of viral reservoirs
  • Studies on the modulation of microbiota in HIV-infected patients
  • Studies on senescence in HIV patients: molecular mechanisms and clinical implication

• Epidemiological research and public health

  • Epidemiological studies based on cohorts (PISCIS, ART-CC, COHERE, EuroSida. PROBE-C)
  • STDs in HIV-infected patients. Epidemiology, diagnosis, treatment, and prevention
  • Prevention strategies: PEP and PrEP
  • Sexualised drug use. Early diagnosis and treatment of HIV, HCV and other STI in this high risk population. 'Chemsex' multidisciplinary management
  • New health-care strategies: telemedicine, shared health-care unit with primary care and OPAT programs
  • HIV infection in adolescent population
  • Anal cancer prevention program in immunosuppressed individuals
  • Chemsex management in MSM population